, , ,

Success Story: Survey of Immune Response to Coronavirus Disease 2019 Infections (SIM-COVID)

Vysnova Partners provides program management support for activities to develop and perform a cross-sectional serology protocol designed to assess the burden and distribution of SARS-CoV-2 infections among US Department of Defense (DoD) forces by measuring antibodies against the SARS-CoV-2 virus.

Vysnova executes a 12-month cross-sectional serology protocol designed to detect the presence of antibodies to SARS-CoV-2 in DoD personnel working or living in USINDOPACOM AOR by conducting a single or repeated cross-sectional serological surveys in order to estimate the prevalence of COVID-19 infections in these populations. Vysnova is also responsible for correlating and comparing results from different serologic assays and the impact of sample type (sera or plasma and saliva or oropharyngeal swab) on assay results. 

A couple of the successes include:

  • Vysnova successfully enrolled 142 subjects in Okinawa
  • 284 of 5ml SST tubes for specimen processing were collected
  • 142 Biolidics RDTs and 142 Right Sign RDTs have been tested